Month: September 2026

Series	RIKB 38 0215			RIKS 50 0915
Settlement Date	09/23/2026			09/23/2026
Total Amount Allocated (MM)	1,780			3,555
All Bids Awarded At (Price / Yield)	95.735	/	7.050	111.920	/	2.810
Total Number of Bids Received	23			20
Total Amount of All Bids Received (MM)	3,860			5,635
Total Number of Successful Bids	14			7
Number of Bids Allocated in Full	14			7
Lowest Price / Highest Yield Allocated	95.735	/	7.050	111.920	/	2.810
Highest Price / Lowest Yield Allocated	96.000	/	7.010	112.220	/	2.794
Lowest Price / Highest Yield Allocated in Full	95.735	/	7.050	111.920	/	2.810
Weighted Average of Successful Bids (Price/Yield)	95.804	/	7.040	112.089	/	2.801
Best Bid (Price / Yield)	96.000	/	7.010	112.220	/	2.794
Worst Bid (Price / Yield)	95.550	/	7.070	111.150	/	2.852
Weighted Average of All Bids Received (Price / Yield)	95.743	/	7.050	111.943	/	2.809
Percentage Partial Allocation (Approximate)	100.00 %			100.00 %
Bid to Cover Ratio	2.17			1.59

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a quarterly ordinary dividend of $0.6175 per share of common stock, which is the equivalent of an annualized dividend of $2.47 per share. The dividend is payable in cash on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.

The board of directors also declared the regular quarterly dividend on the company’s Series I Preferred Stock for the period July 15, 2026 through October 14, 2026 of $0.40625 per share, which is the equivalent of an annualized dividend of $1.625 per share. The dividend is payable in cash on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.

About SL Green Realty Corp.

SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of June 30, 2026, SL Green held interests in 54 buildings totaling 30.6 million square feet, which included ownership interests in 29.2 million square feet and 1.4 million square feet securing debt and preferred equity investments, excluding fund investments, and managed 4 buildings totaling 0.9 million square feet owned by third parties.

Forward Looking Statement

This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, including such matters as future capital expenditures, dividends and acquisitions (including the amount and nature thereof), development trends of the real estate industry and the New York metropolitan area markets, occupancy, business strategies, expansion and growth of our operations and other similar matters, are forward-looking statements. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “continue,” or the negative of these words, or other similar words or terms.

Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise.

PRESS CONTACT
slgreen@berlinrosen.com

SLG – DIV

– FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts –

– Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families –

CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultragenyx Pharmaceutical Inc., on the U.S. Food and Drug Administration (FDA) approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, a gene therapy for the treatment of patients with Sanfilippo syndrome type A (mucopolysaccharidosis IIIA, or MPS IIIA), a rare and progressive neurodegenerative lysosomal storage disorder.

FAYUVI originated from pioneering research conducted by Drs. Haiyan Fu and Douglas McCarty at The Ohio State University and Nationwide Children’s Hospital and was subsequently advanced through clinical development by Abeona Therapeutics as ABO-102. In 2022, Abeona entered into an out-licensing agreement with Ultragenyx granting the company global development and commercialization rights to the program.

“FDA approval of FAYUVI represents an extraordinary milestone for patients and families affected by Sanfilippo syndrome type A, a devastating disease that has lacked effective therapeutic options,” said Vish Seshadri, Chief Executive Officer of Abeona Therapeutics. “The journey to this achievement is a testament to years of scientific innovation and determination across multiple organizations. Abeona was privileged to help advance this program from its academic origins into clinical development, generating the foundational data that supported its continued progress. We are grateful that Ultragenyx continued its advancement through regulatory approval and commend everyone involved in bringing this important therapy to patients.”

The approval of FAYUVI also represents a meaningful value-creation event for Abeona. Pursuant to its licensing agreement with Ultragenyx, Abeona is eligible to receive certain commercial milestone payments and royalties tied to future product sales.

About the FAYUVI development history
Abeona initially advanced the FAYUVI program through critical preclinical and clinical development stages, demonstrating proof-of-concept and establishing safety and efficacy profiles in clinical studies. To ensure the program received the substantial resources required for late-stage development, regulatory filing, and eventual commercialization, Abeona out-licensed the asset to Ultragenyx in May 2022.

About MPS IIIA (Sanfilippo Syndrome Type A)
MPS IIIA is a devastating, progressive, and fatal pediatric neurodegenerative disease caused by a deficiency of the enzyme N-sulfoglucosamine sulfohydrolase, (SGSH), which leads to the accumulation of heparan sulfate in cells throughout the body, particularly in the central nervous system. Children with MPS IIIA experience severe developmental regression, loss of motor skills, and premature death, creating an urgent, high-unmet medical need. FAYUVI is designed to deliver a functional copy of the SGSH gene to the central nervous system via an AAV9 viral vector, addressing the root genetic cause of the disease.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN^® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^®, Abeona Assist^®, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to our ability to maintain existing and obtain additional regulatory approvals of ZEVASKYN® and any future product candidates; our ability to successfully commercialize and market ZEVASKYN® and any future product candidates, if approved, and the timing of any commercialization and marketing efforts; our ability to manufacture sufficient batches of ZEVASKYN® to meet demand; our ability to manufacture ZEVASKYN® batches that meet certain product release specifications that were required by FDA at the time of BLA approval and implemented based on a limited clinical dataset; the FDA’s willingness to revise such release specifications to reflect real-world manufacturing experience; our ability to manufacture from provided biopsy material a ZEVASKYN® batch for which revenue may ultimately be recognized, which depends on such factors as qualified treatment centers obtaining biopsy samples from ZEVASKYN® patients of sufficient quality to act as starting material for manufacturing ZEVASKYN®, patient-to-patient variability in cell growth during the ZEVASKYN® manufacturing process, patient health deterioration in close proximity to ZEVASKYN® treatment such that treatment is no longer possible, and expiration of ZEVASKYN®’s 84-hour shelf-life before surgical application of ZEVASKYN® can be performed; our ability to activate additional qualified treatment centers to administer ZEVASKYN® on patients; the ability of qualified treatment centers to enroll patients for treatment or administer ZEVASKYN® on patients; the ability of our partners to obtain FDA approval and generate revenue from partnered programs and our ability to collect associated royalty and milestone payments; our ability submit an investigational new drug application for ABO-701 and enroll patients in new clinical trials; our ability to access additional financial resources and/or our financial flexibility to reduce operating expenses if required; our ability to obtain additional equity funding from current or new stockholders; the potential impact of unpredicted changes in the structure and/or administration of the United States government or its agencies; our ability to out-license technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount, and sales of assets; the dilutive effect that raising additional funds by selling additional equity securities would have on the relative equity ownership of our existing investors, including under our existing at-the-market sale agreement; the outcome of any interactions with the FDA or other regulatory agencies relating to any of our products or product candidates; our ability to continue to secure and maintain regulatory designations for our product candidates; our ability to develop manufacturing capabilities compliant with current good manufacturing practices for our product candidates; our ability to manufacture cell and gene therapy products and produce an adequate product supply to support clinical trials and potentially future commercialization; the rate and degree of market acceptance of our product candidates for any indication once approved; our ability to meet our obligations contained in license agreements to which we are party; and macroeconomic uncertainty resulting from changes to U.S. trade policy, including current or future tariffs or other trade restrictions.

CONTACT: Contacts:
Investor and Media:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor:
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Ready Capital Corporation (“Ready Capital” or the “Company”) (NYSE: RC) today announced that its subsidiary, ReadyCap Holdings II, LLC (the “Issuer”), has priced a private placement of $225.0 million in aggregate principal amount of 10.00% Senior Secured Notes due 2031 (the “New Notes”). Additionally, ReadyCap Holdings, LLC (“RCH”), a subsidiary of the Company, issued a notice of redemption for the entire $350.0 million outstanding aggregate principal amount of the 4.50% Senior Secured Notes due 2026 (the “Existing Notes”).

The New Notes were priced at 99.5% of principal amount and are expected to close on September 28, 2026. Net proceeds, together with available cash, will be used to redeem the Existing Notes in full at 100% of principal amount plus accrued and unpaid interest. The transaction retires $350.0 million of corporate debt maturing this year, funds approximately two-thirds of that repayment with new capital maturing in 2031 and reduces corporate secured debt outstanding by $125 million.

The redemption of the Existing Notes will complete a material milestone of the Company’s balance sheet repositioning program announced in the fourth quarter of 2025. Over the course of the plan, Ready Capital will have generated approximately $2.3 billion of cash; repaid $1.7 billion of asset-level financing; and retired $549 million of corporate debt. Following the redemption of the Existing Notes, the Company’s sole remaining 2026 corporate debt maturity will be $100.0 million due in November 2026, which the Company expects to repay at maturity from cash on hand.

The Company expects to shift its emphasis from liquidity generation to earnings growth. It intends to deploy capital into current market-yielding originations across its core commercial real estate debt and small business lending platforms.

“In the fourth quarter of 2025, we embarked on a plan to de-lever, generate significant liquidity and reset the balance sheet, and with the $350 million redemption that work is substantially complete,” said Thomas Capasse, Ready Capital’s Chairman and Chief Executive Officer. “This execution demonstrates that investors continue to underwrite the quality of our collateral and the credibility of our business plan. From here our emphasis moves from managing liquidity to growing earnings behind our core CRE and SBA franchises.”

Piper Sandler & Co. acted as the placement agent for the offering. Alston & Bird LLP served as counsel for the Company, and Ropes & Gray LLP served as counsel for the placement agent.

About Ready Capital Corporation

Ready Capital Corporation (NYSE: RC) is a multi-strategy real estate finance company that originates, acquires, finances and services lower-to-middle-market investor and owner occupied commercial real estate loans. The Company specializes in loans backed by commercial real estate, including agency multifamily, investor, construction, and bridge as well as U.S. Small Business Administration loans under its Section 7(a) program. Headquartered in New York, New York, the Company employs over 400 professionals nationwide.

No Offer or Solicitation

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, nor does it constitute a notice of redemption of the Existing Notes. The New Notes and the related guarantees have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws, and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements. The New Notes were offered and will be sold in a private placement in reliance on Section 4(a)(2) of the Securities Act to a limited number of institutional accredited investors as defined in Rule 501(a) of Regulation D. Any redemption of the Existing Notes will be made solely pursuant to the applicable notice of redemption and governing documents.

Safe Harbor Statement

This press release contains statements that constitute “forward-looking statements,” as such term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to be covered by the safe harbor provided by the same. These statements are based on management’s current expectations and beliefs and are subject to a number of trends and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements; the Company can give no assurance that its expectations will be attained. These statements include, without limitation, statements regarding the expected closing of the New Notes offering, the intended redemption of the Existing Notes and the timing thereof, the expected repayment of the Company’s November 2026 corporate debt maturity, the completion of the Company’s balance sheet repositioning plan, and the Company’s expectations regarding future leverage, originations and earnings. Factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, applicable regulatory changes; general volatility of the capital markets; changes in the Company’s investment objectives and business strategy; the availability of financing on acceptable terms or at all; the availability, terms and deployment of capital; the availability of suitable investment opportunities; changes in the interest rates or the general economy; increased rates of default and/or decreased recovery rates on investments; changes in interest rates, interest rate spreads, the yield curve or prepayment rates; changes in prepayments of the Company’s assets; the degree and nature of competition, including competition for the Company’s target assets; and other factors, including those set forth in the Risk Factors section of the Company’s most recent Annual Report on Form 10-K filed with the SEC, and other reports filed by the Company with the SEC, copies of which are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

Investor Relations
Ready Capital Corporation
212-257-4666
InvestorRelations@readycapital.com 
Additional information can be found on the Company’s website at www.readycapital.com. 

AltLens is engineered to measure portfolio risk based on the historical behavior of private markets and make advanced, institutional-level analytics accessible to family offices and small institutional investors

DALLAS, Sept. 18, 2026 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (together with its subsidiaries, the “Company” or “Beneficient”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that it plans to launch AltLens in the fourth quarter of calendar year 2026. AltLens is an alternative asset portfolio analytics and risk platform developed for family offices and small institutional investors. AltLens is designed to help investment teams maintain, organize, and analyze their alternative asset portfolios and assess exposures, allocations against targets and limits, portfolio risk, concentration, and stress-test results.

“Private markets have become too large and too important to the investors we serve for family offices and smaller institutions to rely principally on spreadsheets and public-market proxies to understand portfolio risk,” said James G. Silk, Chief Executive Officer. “We developed AltLens to make sophisticated alternative asset analysis practical for these investors and managers by applying sophisticated risk models to complex private-market data and translating the results into clear analytics that can inform portfolio decisions.”

AltLens maps each portfolio position to specific private-market risk segments defined by asset class, strategy, geography, and sector. For each segment, AltLens maintains a historical series of quarterly returns based on historical private market performance. From these historical returns, AltLens is designed to calculate volatility, beta, value-at-risk, correlation, and concentration metrics. By incorporating historical private-fund performance, the methodology is designed to reflect how private assets have actually behaved rather than analyzing them through a proxy of select publicly traded securities.

The need for alternative asset analytics is expected to grow with the market. Preqin has forecast that alternatives assets under management will reach approximately $29 trillion globally by 2029. As alternative assets account for a larger share of portfolios, family offices and smaller institutions face a growing need for consistent, defensible analysis to support portfolio oversight and investment decisions.

AltLens will also provide historical and hypothetical stress-testing capabilities. Historical scenarios will simulate how a private-market portfolio would perform during markets analogous to the 2008-09 financial crisis, the 2000-03 technology downturn, and the 2021-22 inflationary and rising-interest-rate environment. Users will also be able to model custom hypothetical equity-market declines and interest-rate shocks and evaluate their projected effects by asset class and individual position.

The platform is organized into a set of analytical “lenses” designed to address key portfolio oversight questions: What does the portfolio hold, and how do its allocations compare with applicable targets and limits? What are its principal sources of risk, and where is it concentrated? How might it perform under select stress scenarios? AltLens will deliver the results through dashboards and exportable reports. Using a quarterly portfolio snapshot, the platform is designed to complement a customer’s existing accounting and administration systems.

“Family offices and smaller institutions should not need an enterprise-scale system or a lengthy implementation to conduct sophisticated portfolio risk analysis for alternative assets,” Silk said. “AltLens is designed to fit their quarterly workflow by translating a portfolio snapshot into clear risk and concentration analysis and reports that support investment committee and board decision-making.”

AltLens is part of Beneficient’s broader alternative asset technology platform, under which Beneficient is developing AltSignal, an AI-enabled alternative asset diligence engine, and AltDeal, an enterprise acquisition analysis engine. Beneficient expects to make AltLens available to family offices and small institutional investors in the fourth quarter of calendar year 2026.

About Beneficient

Beneficient (Nasdaq: BENF) – Ben, for short – is on a mission to democratize the global alternative asset investment market by providing traditionally underserved investors − mid-to-high net worth individuals, small-to-midsized institutions and General Partners seeking exit options, anchor commitments and value-added services for their funds – with solutions that could help them unlock the value in their alternative assets.

Its subsidiary, Beneficient Fiduciary Financial, L.L.C., received its charter under the State of Kansas’ Technology-Enabled Fiduciary Financial Institution (TEFFI) Act and is subject to regulatory oversight by the Office of the State Bank Commissioner.

For more information, visit trustben.com or follow us on LinkedIn.

Contacts

Matt Kreps: 214-597-8200, mkreps@darrowir.com

Michael Wetherington: 214-284-1199, mwetherington@darrowir.com

Investor Relations: investors@beneficient.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the planned launch of AltLens in the fourth quarter of calendar year 2026; the expected timing of AltLens’s availability to family offices and small institutional investors; the designed capabilities of AltLens; the anticipated benefits of AltLens and Beneficient’s broader alternative asset technology platform; the expected growth of the alternative asset market and related demand for portfolio analytics and risk-management tools; and the development and anticipated capabilities of AltSignal and AltDeal. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected.

Important factors that could cause actual results to differ materially from those expressed in the forward-looking statements include, among others, risks relating to the timing, development, launch and functionality of AltLens; the risk that the Company is unable to develop, commercialize, or expand AltLens, AltSignal, AltDeal, or its broader alternative asset technology platform; and the other risks, uncertainties, and factors set forth under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and its subsequently filed Quarterly Reports on Form 10-Q, and the risks and uncertainties contained in the Company’s Current Reports on Form 8-K.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

The legendary Chicago restaurant brand will bring its iconic menu items – including its beloved Char-Broiled Burgers – to Buford as it continues its Georgia expansion, marking its second restaurant in the state following the 2025 opening of its Kennesaw location

OAK BROOK, Ill., Sept. 18, 2026 (GLOBE NEWSWIRE) — In honor of National Cheeseburger Day, Portillo’s (NASDAQ: PTLO), the fast-casual restaurant concept known for its menu of unrivaled Chicago-style street food, today announced plans to open a new restaurant in Buford, Georgia, in 2027. The new restaurant will mark Portillo’s second location in Georgia, following the November 2025 opening of its Kennesaw restaurant.

The new Portillo’s will be located at the intersection of Buford Highway (Highway 20) and Mall of Georgia Boulevard. The approximately 4,900-square-foot restaurant will offer seating for nearly 100 guests indoors, plus an additional 20 seats on an outdoor patio. Designed to serve guests however they choose to enjoy Portillo’s, the restaurant will also feature the brand’s signature double drive-thru lanes, Portillo’s Pick-Up shelves, and Grab and Go area for added convenience.

“We’ve felt an incredible welcome from Georgia guests since first opening in Kennesaw last year, and we’re excited to bring even more of what makes Portillo’s special to Buford,” said Brett Patterson, President and Chief Executive Officer of Portillo’s. “As we continue to grow, we’re being thoughtful about where and how we expand, and Buford is a great next step for us. We can’t wait to introduce even more Georgians to the craveable food and one-of-a-kind experience that have made Portillo’s a destination for more than 60 years.”

When Portillo’s Buford opens in 2027, guests can expect to enjoy Portillo’s signature menu of Chicago-style favorites, including Chicago-Style Hot Dogs, famous Italian Beef Sandwiches, Char-Broiled Burgers and Portillo’s classic Chocolate Cake. And with the announcement landing on National Cheeseburger Day, there’s no better time to celebrate the Char-Broiled Burgers that will soon be headed to Buford.

Portillo’s fans can sign up for the latest details about the new Buford restaurant, including hiring opportunities and opening announcements at Portillos.com.

Fans can also join Portillo’s Perks, the brand’s loyalty program, for exclusive offers, experiences and other rewards at Portillos.com/perks. New Perks members will also receive a free large French fry with their first order of $5 or more. Terms and exclusions apply.*

For more information on this restaurant and others, please visit portillos.com or follow Portillo’s on Facebook, X and Instagram, and TikTok.

*New Perks members only. Terms and exclusions apply. Limit 1. See Portillos.com/Perks for more details.

ABOUT PORTILLO’S
Portillo’s (NASDAQ: PTLO) is a one-of-a-kind brand that has grown from a small hot dog trailer in Chicago to more than 100 restaurants across 11 states. Known for its unique menu of craveable Italian beef sandwiches, Chicago-style hot dogs, char-grilled burgers, fresh salads and iconic chocolate cake, Portillo’s is beloved in both its home of Chicagoland and across new and growing markets. Portillo’s operates a company-owned model of not just restaurants – but experience-focused destinations that blend dine-in, drive-thru, takeout and delivery to serve our guests with the food they crave. And now, after six decades of success and counting, Portillo’s is on a mission to bring its iconic food and unforgettable dining experience to guests across the country.

Guests can join Portillo’s Perks, the brand’s loyalty program, at Portillos.com/perks to earn and redeem delicious rewards. Every visit brings fans closer to exclusive perks, badges and surprise offers. Fans can also download the Portillo’s App for iOS or Android or visit Portillo’s website to order ahead for pickup or delivery and get the best dill on these bun-believably delicious Chicago-style favorites and more. Plus, Portillo’s ships its craveworthy food to all 50 states via its website.

MEDIA CONTACT
ICR
PortillosPR@icrinc.com